Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Borderline Personality Disorder

Psychedelics could make mental health worse in people with a personality disorder

by Pouya Movahed Rad
May 4, 2024
in Borderline Personality Disorder, Psychedelic Drugs
Share on TwitterShare on Facebook
Stay informed on the latest psychology and neuroscience research—follow PsyPost on LinkedIn for daily updates and insights.

The interest in psychedelics is growing both in scientific circles and among the public. These are powerful substances capable of altering perception, mood and various mental processes. They also show promise for treating a wide range of mental health disorders.

However, for their use to be safe and effective, it’s important to understand how they interact with different mental health conditions. This is especially true for personality disorders.

A personality disorder is a type of mental disorder involving rigid and unhealthy patterns of thinking, functioning and behaving, which significantly affect a person’s life. Understanding their interaction with psychedelics is crucial. These substances can deeply influence mental states. They can worsen or improve symptoms in ways unique to these disorders.

In a recent study, researchers at Imperial College London investigated the complex relationship between psychedelics and mental health, highlighting the potential risks for people with personality disorders.

The study collected self-reported data from 807 people who used psychedelics in various settings, from recreational to therapeutic. They measured participants’ mental wellbeing before and after using psychedelics using a scale called the Warwick-Edinburgh mental wellbeing scale. The researchers considered it a meaningful drop in mental health if someone’s happiness and wellbeing fell more than what was typical for most people in the study.

The researchers specifically looked at those who had negative experiences while on psychedelics. They found that only 16% of all participants reported an overall negative response. But a significant portion of these negative experiences (31%) were reported by people with a history of personality disorders.

However, the study has several limitations, including the reliance on self-reported data, the small number of participants and a 56% dropout rate. All of these factors would have skewed the results.

Other limitations include the lack of a control group (people given a placebo or standard treatment) for comparison. Additionally, there were variations in the types and dosages of psychedelics used.

The study’s method of participant selection could also lead to biased results. And lumping different personality disorders together might overlook specific risks associated with each.

Different responses

Various personality disorders might respond differently to psychedelics. For instance, people with histrionic personality disorder (excessive attention-seeking and emotional overreaction) or borderline personality disorder (emotional instability, intense relationships and fear of abandonment) might feel worse or more unstable.

And those with schizotypal personality disorder (social anxiety, odd beliefs and eccentric behaviour) could become more paranoid.

People with narcissistic personality disorder (excessive self-importance, lack of empathy, and need for admiration) may struggle with the self-reflective nature of psychedelics because they often have a hard time handling criticism.

Considering the study’s notable limitations, we must approach its findings with some scepticism. Yet the study does recognise the potential benefits of psychedelics for mental health, stressing the need for careful screening for personality disorders.

Using psychedelics safely and effectively requires a personalised approach. This is especially true for vulnerable people. This highlights the importance of refining psychedelic therapy to make it safe and effective for all.

As we explore the expanding territory of psychedelic therapy, it’s vital to understand how these substances interact with mental health conditions – including personality disorders.

We must use more rigorous methods, such as controlled trials to compare psychedelics to standard treatments or a placebo. Personality disorders should also be verified via professional evaluation, not just self-reports. And, finally, psychedelic doses need to be uniform in order to reliably assess their therapeutic effect.The Conversation

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

RELATED

Psychedelic mushrooms and quiet quitting: Psilocybin use tied to working fewer overtime hours
Depression

Psilocybin therapy linked to lasting depression remission five years later

October 27, 2025
LSD might have a small positive effect when used to treat substance use disorders
LSD

LSD might have a small positive effect when used to treat substance use disorders

October 22, 2025
Psychedelic experiences linked to reduced cannabis use and greater psychological flexibility
Addiction

Psychedelic experiences linked to reduced cannabis use and greater psychological flexibility

October 17, 2025
Futuristic digital illustration of a human brain with neural networks and bright colors, representing psychology, neuroscience, and mental health research.
Ayahuasca

Long-term ayahuasca use linked to distinct emotional brain activity and higher resilience

October 14, 2025
New study highlights psilocybin’s promise for major depressive disorder treatment
Psilocybin

Psilocybin therapy linked to reduced suicidal thoughts in people with psychiatric disorders

October 9, 2025
Scientists studied ayahuasca users—what they found about death is stunning
Ayahuasca

Scientists studied ayahuasca users—what they found about death is stunning

October 8, 2025
Psilocybin-assisted group therapy may help reduce depression and burnout among healthcare workers
Psilocybin

Psilocybin-assisted group therapy may help reduce depression and burnout among healthcare workers

October 4, 2025
Vivid digital artwork of a human brain with colorful neural pathways and energetic patterns, illustrating neuroscience, psychology, and brain activity concepts.
Psychedelic Drugs

Psychedelics may not boost creativity as widely believed, new study suggests

September 28, 2025

PsyPost Merch

STAY CONNECTED

LATEST

ADHD’s “stuck in the present” nature may be rooted in specific brain network communication

Two simple cognitive tendencies emerge as surprisingly powerful predictors of belief in pseudoscience

Liberals prefer brands that give employees more freedom, study finds

Music reorganizes brain activity to enhance our sense of time

What connects childhood trauma to aggression in teens with gaming disorder?

Energy insecurity linked to higher rates of depression and anxiety

A subtle sign could predict Alzheimer’s or Parkinson’s years in advance

Trauma history shapes how the brain adaptively responds to new stress

RSS Psychology of Selling

  • Rethink your global strategy: Research reveals when to lead with the heart or the head
  • What five studies reveal about Black Friday misbehavior
  • How personal happiness shapes workplace flourishing among retail salespeople
  • Are sales won by skill or flexibility? A look inside investment banking sales strategies
  • Toxic leadership: How narcissistic bosses shape nurses’ workplaces
         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy